Adjuvant Trastuzumab Plus Pyrotinib for Residual Invasive HER2-positive Breast Cancer After Neoadjuvant Chemotherapy Plus Anti-HER2 Target Therapy
Latest Information Update: 24 Nov 2023
At a glance
- Drugs Pyrotinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
Most Recent Events
- 18 Nov 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2026.
- 19 Apr 2022 Status changed from not yet recruiting to recruiting.
- 11 Feb 2020 New trial record